Evidence map›Paper›PMID 42353613›Full record

ArticleCurrent issues in molecular biology2026

Effects of Different Doses of Ranolazine on SIRT1, APELA, and APL13 in a Rat MCAO Model.

Abdulkadir Kankilic, Ibrahim Basar, Selim Karahan, Ulas Alabalik, Revsa Evin Canpolat Erkan, Omer Karakoyun, Ismail Yildiz, Mehmet Yigit Akgun, Ozkan Ates, Meral Erdinc

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Abdulkadir KankilicDepartment of Neurosurgery, Faculty of Medicine, Dicle University, 21280 Diyarbakır, Türkiye.ORCID 0009-0002-9402-9180
Ibrahim BasarDepartment of Neurosurgery, Faculty of Medicine, Dicle University, 21280 Diyarbakır, Türkiye.
Selim KarahanDepartment of Medical Pharmacology, Faculty of Medicine, Mardin Artuklu University, 47200 Mardin, Türkiye.ORCID 0000-0001-5784-7091
Ulas AlabalikDepartment of Pathology, Faculty of Medicine, Dicle University, 21280 Diyarbakır, Türkiye.
Revsa Evin Canpolat ErkanDepartment of Biochemistry, Faculty of Medicine, Dicle University, 21280 Diyarbakır, Türkiye.
Omer KarakoyunDepartment of Dermatology and Venereology, Gazi Yaşargil Training and Research Hospital, 21010 Diyarbakır, Türkiye.ORCID 0009-0008-8196-7470
Ismail YildizDepartment of Biostatistics, Faculty of Medicine, Dicle University, 21280 Diyarbakır, Türkiye.ORCID 0000-0001-5505-838X
Mehmet Yigit AkgunDepartment of Neurosurgery, Faculty of Medicine, Koç University, 34010 Istanbul, Türkiye.ORCID 0000-0003-1342-7663
Ozkan AtesDepartment of Neurosurgery, Faculty of Medicine, Koç University, 34010 Istanbul, Türkiye.
Meral ErdincDepartment of Medical Pharmacology, Faculty of Medicine, Dicle University, 21280 Diyarbakır, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study investigated the effects of different doses of ranolazine in a middle cerebral artery occlusion/reperfusion (MCAO-I/R) model by evaluating histopathological changes and serum Sirtuin 1 (SIRT1), Apela peptide (APELA), and Apelin-13 (APL13) levels. A total of 47 male Sprague Dawley rats (250 ± 20 g) were randomly assigned to five groups: Sham (

Indexed as

APELAAPL13MCAOneuroprotectionranolazineSIRT1

Identifiers

PMID42353613
PMCPMC13298514

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.